Hereditary breast cancer growth rates and its impact on screening policy
Madeleine M.A. Tilanus‐Linthorst(Erasmus University Rotterdam), Cecile T.M. Brekelmans(Erasmus MC), Hans Peterse(The Netherlands Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Harry J. de Koning(Erasmus MC), C. Boetes(Radboud University Nijmegen), Jan C. Oosterwijk(University Medical Center Groningen), Harmine M. Zonderland, Sybren Meijer(Erasmus MC Cancer Institute), Wim C.J. Hop, Inge-Marie Obdeijn, Jan G.M. Klijn(German Cancer Research Center), Mieke Kriege
Cited by 76
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k